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Abstract
Background: ZNF217 is a candidate oncogene located at 20q13, a chromosomal region frequently amplified in
breast cancers. The precise mechanisms involved in ZNF217 pro-survival function are currently unknown, and
utmost importance is given to deciphering the role of ZNF217 in cancer therapy response.
Results: We provide evidence that stable overexpression of ZNF217 in MDA-MB-231 breast cancer cells conferred
resistance to paclitaxel, stimulated cell proliferation in vitro associated with aberrant expression of several cyclins,
and increased tumor growth in mouse xenograft models. Conversely, siRNA-mediated silencing of ZNF217
expression in MCF7 breast cancer cells, which possess high endogenous levels of ZNF217, led to decreased cell
proliferation and increased sensitivity to paclitaxel. The paclitaxel resistance developed by ZNF217-overexpressing
MDA-MB-231 cells was not mediated by the ABCB1/PgP transporter. However, ZNF217 was able to counteract the
apoptotic signals mediated by paclitaxel as a consequence of alterations in the intrinsic apoptotic pathway
through constitutive deregulation of the balance of Bcl-2 family proteins. Interestingly, ZNF217 expression levels
were correlated with the oncogenic kinase Aurora-A expression levels, as ZNF217 overexpression led to increased
expression of the Aurora-A protein, whereas ZNF217 silencing was associated with low Aurora-A expression levels.
We showed that a potent Aurora-A kinase inhibitor was able to reverse paclitaxel resistance in the ZNF217-
overexpressing cells.
Conclusion: Altogether, these data suggest that ZNF217 might play an important role in breast neoplastic
progression and chemoresistance, and that Aurora-A might be involved in ZNF217-mediated effects.
Background
In breast cancer, the 20q13 region is amplified in up to
29% of tumors and is associated with early stage, aggres-
sive phenotype and poor clinical prognosis [1]. A num-
ber of genes located on chromosome 20q13, such as
AURKA/STK15 [2], EEF1A2 [3] and ZNF217 [4], appear
as possible oncogenic targets of amplification. ZNF217
amplification correlates with shorter patient survival in
breast [5] and in ovarian cancers [6]. The first direct
evidence for a potentially oncogenic function of ZNF217
was the demonstration that the transduction of finite
life-span human mammary epithelial cells with ZNF217
could give rise to immortalized cells with increased telo-
merase activity and stabilized telomere length [7]. It has
been hypothesized that the selective amplification of
ZNF217 allows cancer cells to overcome senescence and
become immortal, a requirement likely essential for can-
cer development [8]. In support of this original study,
ZNF217 has also recently been shown to immortalize
ovarian cells [9].
ZNF217 is a Krüppel-like zinc finger protein that loca-
lizes to the nucleus [10] and interacts with co-repressors
and histone modifying proteins [11-13], suggesting that
ZNF217 may be part of a transcriptional repressor com-
plex. ZNF217 promotes cell viability in HeLa cells by
interfering with the apoptotic pathway and attenuates
apoptotic signals resulting from doxorubicin-induced
DNA damage or from functionally compromised
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presses the formation of cell colonies and invasion [15].
Finally, activation of the Akt pathway [14] and overex-
pression of the oncogenic translation elongation factor
eEF1A2 [16] have been proposed to mediate ZNF217
tumorigenic functions, but the precise molecular
mechanisms involved in ZNF217 pro-survival function
are currently unknown.
This study aimed to decipher the contribution of
ZNF217 in cancer therapy response and to determine
whether ZNF217 is able to counteract apoptotic signals
other than those induced by DNA damage stimuli. Tax-
anes are microtubule-stabilizing agents that, by interfer-
ing with spindle microtubule dynamics, cause cell cycle
arrest and apoptosis. While paclitaxel is recognized as
an extremely active chemotherapeutic agent in the treat-
ment of early-stage or metastatic breast cancers, resis-
tance to paclitaxel has become a major concern [17]. In
this study, we investigated the functional consequences
of aberrant ZNF217 expression on breast cancer cell
behavior. We found that ZNF217 confers a highly prolif-
erative and paclitaxel-resistant phenotype to MDA-MB-
231 breast cancer cells. To decipher the molecular
mechanisms likely responsible for such phenotype, we
investigated the possible involvement of the ABCB1/Pgp
transporter, of the intrinsic apoptotic pathway and of
the oncogenic kinase Aurora-A.
Results
Establishment of stable ZNF217 transfectants of breast
cancer cells
With the aim of selecting relevant breast cancer cell
lines to study the impact of ZNF217 expression on
breast cancer cell phenotype, we analyzed ZNF217
mRNA and ZNF217 protein levels in MCF7 and MDA-
MB-231 breast cancer cells. As shown in Figures 1A
and 1B, MCF7 and MDA-MB-231 cells possess, respec-
tively, high and low endogenous ZNF217 mRNA and
protein levels. The high expression level of ZNF217 in
MCF7 cells is consistent with the amplification of the
20q13 region in these cells [4]. However, this correlation
was more difficult to establish in MDA-MB-231 cells, as
the 20q13 genomic status in these cells is controversial
[18,19]. Given that MDA-MB-231 cells possess low
endogenous levels of ZNF217, they were used to estab-
lish stable MDA-MB-231 cells constitutively overexpres-
sing the ZNF217 protein. After blasticidin selection, two
cell clones overexpressing ZNF217 mRNA and ZNF217
protein (named ZNF217-1 and ZNF217-2), as well as a
control cell clone transfected with the empty pcDNA6/
V5-His vector (called MDA-MB-231/pcDNA6), were
selected. ZNF217 mRNA levels were respectively 2.0-
and 3.5-fold greater in ZNF217-1 and ZNF217-2 cells
than in MDA-MB-231/pcDNA6 controls (Figure 1C).
Accordingly, ZNF217 protein expression was increased
by 5.4- and 5.1-fold in ZNF217-1 and ZNF217-2 cells,
respectively, as compared to controls (Figure 1D).
Constitutive expression of ZNF217 in MDA-MB-231 breast
cancer cells promotes cell proliferation in vitro and tumor
growth in vivo
By performing a BrdU incorporation assay (measure-
ment of the proportion of cells entering S phase), we
found that the constitutive expression of ZNF217 led to
a significant increased proliferation of both ZNF217-1
and ZNF217-2 cells, compared to MDA-MB-231/
pcDNA6 controls (Figure 2A). The ability of ZNF217
clones to proliferate more rapidly was correlated with
the overexpression of Cyclin D1, Cyclin E1, Cyclin E2
and Cyclin A2 proteins, as assessed by western-blot
analysis (Figure 2B). Using two siRNA molecules
(-A and -B) that both specifically promote the knock-
down of ZNF217 expression at the mRNA (data not
shown) and protein levels in MDA-MB-231/pcDNA6
and ZNF217-1 cells (Figures 3A and 3B), we could
establish that ZNF217 plays a direct role in conferring
stimulation of cell proliferation. Indeed, transient trans-
fections with the two ZNF217-targeted siRNAs led to a
significant decrease in cell proliferation both in MDA-
MB-231/pcDNA6 control cells (Figure 3C) and in
ZNF217-overexpressing cells ZNF217-1 (Figure 3D).
Again, when targeting the high endogenous levels of
ZNF217 present in MCF7 cells, a similar cytostatic
activity could be obtained with the siRNAs -A and -B
(Figures 3E and 3F). Interestingly, the most potent cyto-
static effect was observed in the presence of siRNA-B
which was able to induce complete knock-down of
ZNF217 protein expression, while siRNA-A, which pro-
motes an intermediate knock-down of ZNF217 protein,
led to an intermediate but still significant decrease in
cell proliferation (Figures 3E and 3F). Taken together,
these data suggest that: (i) even though breast cancer
cells possess low ZNF217 levels, knock-down of ZNF217
endogenous protein expression dramatically affects their
proliferation (Figures 3C and 3F); (ii) the negative regu-
lation of cell proliferation observed with decreased levels
of ZNF217 is exerted in a dose-dependent manner
(Figure 3F). Finally, we examined whether the constitu-
tive expression of ZNF217 in MDA-MB-231 cells would
affect their growth in nude mice. To address this ques-
tion, xenografts were established by injecting MDA-MB-
231/pcDNA6 control cells or ZNF217-1 cells into the
mammary fat pads of female nude mice. A significant
increase in tumor growth was observed in mice injected
with ZNF217-1 cells as compared with those receiving
control cells (Figure 4A). Western-blot analysis of
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Page 2 of 17protein lysates collected from xenografts confirmed the
high expression levels of both ZNF217 and Cyclin D1 in
ZNF217 tumors (Figure 4B).
ZNF217 overexpression confers paclitaxel resistance in
MDA-MB-231 cells
To test whether ZNF217 alters response to chemother-
apy, we performed dose-response experiments (cytotoxi-
city assay) to measure IC50 values under two cytotoxic
stimuli: paclitaxel and gemcitabine. Strikingly, constitu-
tive expression of ZNF217 led to significant increased
cell viability in the presence of the microtubule-stabiliz-
ing agent paclitaxel (Figure 5A), with a relative resis-
tance of 7.5- and 12-fold, respectively, for ZNF217-1
and ZNF217-2 cells (IC50MDA-MB-231/pcDNA6 =6 . 5±
1.4×10
-10 M, IC50ZNF217-1 =4 . 9±1 . 7 × 1 0
-9 M,
IC50ZNF217-2 =7 . 8±0 . 6 × 1 0
-9 M). Interestingly, MCF7
cells, which possess high endogenous levels of ZNF217,
displayed lower sensitivity to paclitaxel (IC50MCF7 =2 . 2
±0 . 7 × 1 0
-7 M) than MDA-MB-231/pcDNA6 cells
(Figure 5B). Moreover, the knock-down of ZNF217
expression in MCF7 cells by transient transfections with
Figure 1 ZNF217 expression in MCF7, MDA-MB-231 and pcDNA6/V5-His-ZNF217-transfected MDA-MB-231 cells.( A) ZNF217 mRNA
expression was analyzed by RTQ-PCR in MCF7 and MDA-MB-231 cells (means ± s.d. of three independent experiments). (B) western-blot analysis
of ZNF217 in MCF7 and MDA-MB-231 cell lines. Histograms represent quantification of protein expression levels normalized to tubulin expression
(means ± s.d. of three independent experiments). ***, P < 0.001 (Student’s t-test). (C) The same as (A) in ZNF217-overexpressing MDA-MB-231
cells, ZNF217-1 and ZNF217-2. (D) The same as (B) in ZNF217-1, ZNF217-2 and in control MDA-MB-231/pcDNA6 cells.
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Page 3 of 17Figure 2 Constitutive expression of ZNF217 stimulates cell proliferation in vitro.( A) Cell proliferation was assessed at different time points
by BrdU labeling (means ± s.d. of three independent experiments). **, P < 0.01 versus MDA-MB-231/pcDNA6 cells (Student’s t-test). (B) Western-
blot analysis of Cyclin D1, Cyclin E1, Cyclin E2 and Cyclin A2. Histograms represent quantification of protein expression levels normalized to
tubulin expression (means ± s.d. of three independent experiments). **, P < 0.01 and ***, P < 0.001 versus MDA-MB-231/pcDNA6 cells (Student’s
t-test).
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Page 4 of 17Figure 3 Decreased levels of ZNF217 negatively regulates cell proliferation in vitro.( A) Western-blot analysis of ZNF217 expression in non-
transfected (NT) or transfected MDA-MB-231/pcDNA6 cells with either scrambled RNA, siRNA-B or siRNA-A. Histograms represent quantification of
protein expression levels normalized to tubulin expression (means ± s.d. of three independent experiments). (B) the same as (A) using the
ZNF217-1 cell line. (C) Cell proliferation of non-transfected (NT) or transfected MDA-MB-231/pcDNA6 cells with either scrambled RNA, siRNA-B or
siRNA-A as assessed by BrdU test. (D) the same as (C) using the ZNF217-1 cell line. (E) and (F) respectively the same as (A) and (C) using MCF7
cells. *, P < 0.05, **, P < 0.01 and ***, P < 0.001 versus cells transfected with scrambled RNA (Student’s t-test).
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Page 5 of 17Figure 4 Constitutive expression of ZNF217 stimulates tumor growth in vivo.( A) Growth curves of control xenografts (n = 6) and ZNF217
xenografts (n = 7) in nude mice. Data are presented as means ± s.d. of tumor volumes. *, P < 0.05, **, P < 0.01 and ***, P < 0.001 (Student’s
t-test). (B) Representative total protein extracts from control and ZNF217 xenografts were analyzed by western-blot with anti-ZNF217 and anti-
Cyclin D1 antibodies. Histogram represents quantification of protein expression levels normalized to tubulin expression (means ± s.d. of three
independent experiments). ***, P < 0.001 (Student’s t-test).
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(IC50siRNA-B-transfected MCF7 =4±0 . 7 × 1 0
-9 M,
IC50scrambled-transfected MCF7 =2 . 2±0 . 7 × 1 0
-7 M) (Figure
5B). These data suggest that ZNF217 is able to modulate
the cellular response to paclitaxel and that the constitu-
tive expression of ZNF217 supports the survival of
MDA-MB-231 cells in response to this microtubule-sta-
bilizing molecule. In contrast, no significant difference
in gemcitabine response could be observed between
ZNF217-overexpressing cells and controls (data not
shown). Finally, paclitaxel resistance could also be
observed in an additional breast cancer cell line (MDA-
MB-453) stably transfected with ZNF217 when com-
pared to control cells (data not shown), suggesting that
the paclitaxel-resistant phenotype developed by
ZNF217-overexpressing cells occurs in different breast
cancer cell lines.
ABCB1/PgP transporter is not involved in the paclitaxel
resistance developed by ZNF217-overexpressing cells
Cancer cells frequently exhibit multidrug resistance
mediated by ATP-binding cassette (ABC) membrane
proteins. The ABCB1/PgP protein efficiently transports
taxanes and its overexpression induces resistance to
paclitaxel [20]. We thus evaluated ABCB1 expression
levels and transport capabilities in MDA-MB-231/
pcDNA6 controls, ZNF217-1 and ZNF217-2 cells. Very
low and similar ABCB1 endogenous expression levels
were detected in all three cell lines, while it was strongly
detected in K562-R7 ABCB1-positive control cells (Fig-
ure 6A). To evaluate ABCB1 transport capabilities, we
then used a standard test that investigates the efflux of
daunorubicin (DNR), a well-known fluorescent substrate
of ABCB1 that binds to the same binding sites as pacli-
taxel on the transporter [21-24]. Inhibitors such as
Figure 5 ZNF217 expression induces resistance to paclitaxel. Cell viability of (A) MDA-MB-231/pcDNA6, ZNF217-1 and ZNF217-2 cells and
(B) non-transfected (NT) or transfected MCF7 cells with either scrambled RNA or siRNA-B was assessed by cytotoxicity assay (means ± s.d. from
three independent experiments). **, P < 0.01, ***, P < 0.001 (Student’s t-test).
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Page 7 of 17Figure 6 ABCB1/PgP transporter does not mediate ZNF217-induced resistance to paclitaxel.( A) ABCB1 protein levels were analyzed by
flow cytometry in control K562-R7, MDA-MB-231/pcDNA6, ZNF217-1 and ZNF217-2 cells. Representative FACS histograms of the three cell lines
after incubation with or without ABCB1 antibody were superimposed according to increased PE fluorescence. (B) Intracellular DNR efflux was
assessed by flow cytometry. Maximal DNR accumulation (100%) is represented by the DNR fluorescence median after 30 min accumulation. After
DNR removal, cells were incubated 1 h in the absence (white columns) or in the presence of CSA (black columns). Results are means ± s.d. from
three independent experiments.
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Page 8 of 17cyclosporin A (CSA), a reference ABC transporter inhi-
bitor, reduce DNR efflux in cells that have an active
mechanism for the outward transport of the drug [24].
W ec o n f i r m e dt h a tC S Aw a sa b l et os t r o n g l yb l o c k
DNR efflux in K562-R7 ABCB1-positive cells (Figure
6B). DNR intracellular levels were similarly decreased in
MDA-MB-231/pcDNA6, ZNF217-1 and ZNF217-2 cells
after a 1 h efflux period, thus revealing no difference
between the three cell lines. Moreover, as DNR intracel-
lular levels were not altered in the presence of CSA,
CSA-insensitive elimination processes were probably
responsible for the DNR efflux observed in the three
cell lines. Since both ABCB1 was weakly expressed in
cells and DNR efflux was not modified by CSA, our
data strongly suggest that ABCB1 was not involved in
the paclitaxel-resistance mechanisms developed by
ZNF217-overexpressing MDA-MB-231 cells.
Paclitaxel-induced apoptotic activity is altered in ZNF217-
overexpressing MDA-MB-231 cells
As paclitaxel has been shown to induce apoptosis in
several cell lines in a dose-dependent manner [25,26],
we investigated the impact of ZNF217 expression on
paclitaxel pro-apoptotic signals. We confirmed that
paclitaxel was able to elicit cell death in MDA-MB-231/
pcDNA6 cells in a dose-dependent manner (10 nM and
100 nM paclitaxel induced apoptosis in respectively
45.1% and 69.6% of the cells, Figure 7A). In ZNF217-
overexpressing cells, no decreased spontaneous cell
death could be observed at basal level compared to con-
trol cells (Figure 7A), in contrast to results reported by
Huang and collaborators in ZNF217-overexpressing
HeLa cells [14] and no significant difference could be
observed between the three cell lines (Figure 7A). How-
ever, 10 nM and 100 nM paclitaxel strikingly elicited a
significant lower apoptotic response in ZNF217-overex-
pressing cells than in controls (Figure 7A). As the maxi-
mum paclitaxel-induced apoptotic response was
observed with 100 nM paclitaxel, this dose was chosen
for further investigations. Measurement of caspase 3
activity also provided evidence that apoptotic pathways
were significantly less activated in ZNF217-1 and
ZNF217-2 cells than in control cells (Figure 7B). Sup-
porting data showed that, in MDA-MB-231/pcDNA6
controls, 100 nM paclitaxel induced cleavage of the
PARP protein which was only faintly detectable in
ZNF217-1 cells and absent in ZNF217-2 cells (Figure
7C). Finally, transient transfection of MCF7 cells with a
ZNF217-targeted siRNA (compared to scrambled con-
trol RNA) led to a significant increase in caspase 3
activity on paclitaxel treatment (Figure 7D), suggesting
t h a tt h ek n o c k - d o w no fZ N F 2 1 7e x p r e s s i o ni nM C F 7
cells confers increased sensitivity to paclitaxel pro-apop-
totic signals. Altogether, these data suggest that
constitutive ZNF217 expression confers resistance to
paclitaxel-mediated apoptosis.
Acquired resistance to paclitaxel in ZNF217-
overexpressing cells is mediated by alterations of
proteins of the Bcl-2 family implicated in the
mitochondrial apoptosis pathway
In breast cancer cells that acquired resistance to pacli-
taxel, it has been recently demonstrated that the mito-
chondrial (intrinsic) apoptosis pathway controlled by
Bcl-2 protein family members is crucial for causing such
resistance [27]. We thus examined whether changes in
the mitochondrial apoptotic pathway were selected for
in ZNF217-overexpressing cells. Because we were inter-
ested by permanent changes established under constitu-
tive expression of ZNF217, we first evaluated the effect
of ZNF217 on the levels of several Bcl-2 family proteins.
In the two ZNF217-overexpressing cell lines studied, we
observed a constitutive overexpression of the anti-apop-
totic proteins Bcl-2 and Bcl-xL and an under-expression
of the pro-apoptotic proteins Bad, Bak and Bax (Figure
8A), as compared to MDA-MB-231/pcDNA6 controls.
Moreover, as shown in Figure 8B, treatment with 10 nM
or 100 nM paclitaxel was still associated with the over-
expression of Bcl-2 and Bcl-xL and the down-regulation
of Bad in both ZNF217-1 and ZNF217-2 cell lines. The
persistence of the deregulated expression levels observed
for Bcl-2, Bcl-xL and Bad under paclitaxel exposure was
less obvious for Bak and Bax proteins, as it depended on
the paclitaxel dose and on the ZNF217-overexpressing
clone considered. Taken together, these results indicate
that the resistance to paclitaxel displayed by ZNF217-
overexpressing cells might be promoted by deregulations
of the intrinsic apoptosis pathway through aberrant
expression of several members of the Bcl-2 family.
Increased protein expression of the Aurora kinase A/
AURKA/STK15 is correlated with constitutive expression
of ZNF217 and ZNF217-mediated paclitaxel resistance is
reversed in the presence of an Aurora-A inhibitor
Since high expression levels of Aurora-A have been
associated with increased taxane resistance in breast
cancer and with resistance to taxol-mediated apoptosis
in breast cancer cell lines [28,29], we investigated Aur-
ora-A expression levels in our cellular models. Strik-
ingly, high protein expression levels of Aurora-A could
be detected in the two ZNF217-overexpressing cell lines
(Figure 9A) and in ZNF217 xenografts (Figure 9B).
ZNF217 was demonstrated to play a direct role in Aur-
ora-A overexpression, as transient transfections with a
ZNF217-targeted siRNA led to a significant decrease in
Aurora-A protein expression both in ZNF217-1 and in
MCF7 cells (that possess naturally high endogenous
levels of ZNF217) (Figure 9C). As ZNF217 has been
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Page 9 of 17Figure 7 ZNF217 overexpression alters paclitaxel-induced apoptosis.( A) MDA-MB-231/pcDNA6, ZNF217-1 and ZNF217-2 cells were
untreated (-) or treated with 10 or 100 nM paclitaxel, stained with Annexin-V-Fluos and propidium iodide and analyzed by flow cytometry
(means ± s.d. from three independent experiments). **, P < 0.01 and ***, P < 0.001 versus the corresponding MDA-MB-231/pcDNA6 cells
(Student’s t-test). (B) MDA-MB-231/pcDNA6, ZNF217-1 and ZNF217-2 cells were treated with 100 nM paclitaxel. Caspase 3 activity was assessed
(means ± s.d. from three independent experiments). ***, P < 0.001 versus MDA-MB-231/pcDNA6 cells (Student’s t-test). (C) Western-blot analysis
of PARP cleavage in response to 100 nM paclitaxel. Histogram represents quantification of the cleaved PARP in 100 nM paclitaxel-treated cells
and tubulin expression was used for normalization (means ± s.d. of three independent experiments). ***, P < 0.001 versus paclitaxel-treated MDA-
MB-231/pcDNA6 cells (Student’s t-test). (D) Non-transfected (NT) or transfected MCF7 cells with either scrambled RNA or siRNA-B were treated
with 100 nM paclitaxel. Caspase 3 activity was assessed (means ± s.d. from three independent experiments). *, P < 0.05 versus MCF7 cells
transfected with scrambled RNA (Student’s t-test).
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PCR AURKA transcript levels in MDA-MB-231/
pcDNA6, ZNF217-1, and ZNF217-2 cells, but we did
not find any difference between the three cell lines (data
not shown). This suggests that the ZNF217-mediated
aberrant expression of Aurora-A is probably controlled
by a post-transcriptional mechanism.
With the aim to decipher whether Aurora-A is
involved in the paclitaxel resistance developed by the
ZNF217-overexpressing cells, we then sought to investi-
gate the impact of an Aurora-A kinase inhibitor on
paclitaxel response. The Aurora kinase inhibitor III is a
compound known to act as an ATP-competitive and
potent inhibitor of Aurora-A( M e r c k ) .T h i si n h i b i t o r
Figure 8 ZNF217 overexpression is associated with altered expression of Bcl-2 family proteins.( A) Western-blot analysis of Bcl-2, Bcl-xL,
Bad, Bak, Bax at basal level or (B) after 3 days of paclitaxel treatment. Histograms represent quantification of protein expression levels normalized
to tubulin expression (means ± s.d. of three independent experiments). *, P < 0.05, **, P < 0.01 and ***, P < 0.001 versus the corresponding
MDA-MB-231/pcDNA6 cells (Student’s t-test).
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Page 11 of 17Figure 9 ZNF217 modulates Aurora-A protein expression and ZNF217-mediated paclitaxel resistance is reversed by an Aurora-A
inhibitor. Western-blot analysis of Aurora-A expression in (A) MDA-MB-231/pcDNA6, ZNF217-1 and ZNF217-2 cells, (B) in representative control
and ZNF217 xenograft cells, (C) in ZNF217-1 or MCF7 cells transfected or not (NT) with either scrambled RNA or siRNA-B. (A), (B) and (C)
Histograms represent quantification of protein expression levels normalized to tubulin expression (means ± s.d. of three independent
experiments). *, P < 0.05 and ***, P < 0.001 (Student’s t-test). (D) The viability of MDA-MB-231/pcDNA6 and ZNF217-1 cells treated with 5 μM
Aurora-A kinase inhibitor III, 2.5 nM paclitaxel or a combination of both was assessed by cytotoxicity assay (means ± s.d. from three independent
experiments). ***, P < 0.001 (Student’s t-test). (E) MCF7 cells transfected with either scrambled RNA or siRNA-B were treated with 1 μM Aurora-A
kinase inhibitor III, 2.5 nM paclitaxel or a combination of both. Cell viability was assessed by cytotoxicity assay (means ± s.d. from three
independent experiments). **, P < 0.01 (Student’s t-test).
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Page 12 of 17(5 μM) exerted a weak and similar inhibitory effect
(~10%) on viability of both MDA-MB-231/pcDNA6 and
ZNF217-1 cells (Figure 9D). In control MDA-MB-231/
pcDNA6 cells, combining 5 μM Aurora-A kinase inhibi-
tor with paclitaxel led to an additive inhibitory effect of
the two molecules on cell viability (51.5% inhibition
under paclitaxel exposure and 63.6% inhibition when
combining the Aurora-A kinase inhibitor with pacli-
taxel). Strikingly, in ZNF217-1 cells, combining 5 μM
Aurora-A kinase inhibitor with paclitaxel potentialized
paclitaxel cytotoxic effect (Figure 9D, 57% of inhibition
of cell viability in Aurora-A kinase inhibitor- and pacli-
taxel-treated ZNF217-1 cells compared to 24% inhibi-
tion of cell viability in paclitaxel-treated ZNF217-1 cells,
P < 0.001), and induced a pharmacological response
close to that of control paclitaxel-treated MDA-MB-
231/pcDNA6 cells. We next investigated the impact of
the Aurora-A kinase inhibitor on paclitaxel response in
MCF7 cells transfected with either a ZNF217-targeted
siRNA or scrambled RNA (Figure 9E). In MCF7 cells
transiently transfected with scrambled control RNA (i.e.
still possessing high endogenous levels of ZNF217),
combining the Aurora-A kinase inhibitor with paclitaxel
led to an additive inhibitory effect on cell viability, as
observed in ZNF217-overexpressing MDA-MB-231 cells
( F i g u r e9 D ) .M o r ei n t e r e s t i ngly, combining paclitaxel
with the Aurora-A inhibitor in MCF7 cells transiently
transfected with a ZNF217-targeted siRNA induced no
significant alteration of cell viability (as observed in the
control MDA-MB-231/pcDNA6 cells that possess low
endogenous levels of ZNF217, Figure 9D). Taken
together, these data strongly suggest that the impact of
the Aurora-A inhibitor on paclitaxel response is clearly
associated with ZNF217 expression levels. Therefore
Aurora-A is certainly part of the mechanism by which
ZNF217 controls resistance to paclitaxel, and the use of
a potent Aurora-A inhibitor could be sufficient to
reverse ZNF217-mediated paclitaxel resistance in MDA-
MB-231 breast cancer cells.
Discussion
It has been shown that ZNF217 is able to immortalize
human mammary epithelial cells, to overcome senes-
cence and to attenuate apoptotic signals emanating from
DNA damage after doxorubicin exposure or from func-
tionally compromised telomeres [7,14]. The precise
mechanisms involved in ZNF217 pro-survival function
are currently unknown, and it is thus of utmost impor-
tance to decipher the role of ZNF217 in response to
cancer therapy.
In this study, we provide evidence that ectopic expres-
sion of ZNF217 in MDA-MB-231 breast cancer cells is
associated with a highly proliferative phenotype, as con-
stitutive expression of ZNF217 stimulates breast cancer
cell proliferation in vitro and tumor growth in vivo in
association with aberrant expression of several cyclins.
We have also found that high expression levels of
ZNF217 in MDA-MB-231 breast cancer cells promote
strong resistance (~10-fold) to the microtubule-stabiliz-
ing molecule paclitaxel, while no resistance to the
nucleoside analogue gemcitabine is concomitantly devel-
oped. In accordance with the previous observation that
overexpression of ZNF217 decreases doxorubicin-
induced cell death in cervical (HeLa) and breast
(HBL100) cancer cell lines [14], the two ZNF217-over-
expressing MDA-MB-231 cell lines studied also dis-
played a ~2.3-fold relative resistance to the
topoisomerase inhibitor doxorubicin (data not shown).
Our data suggest, firstly, that the chemoresistance
mediated by ZNF217 is drug-specific and, secondly, that
the molecular mechanisms involved in paclitaxel
response are probably more sensitive to the ZNF217-
mediated protective action than those involved in
response to doxorubicin.
After pointing out that the ABCB1 transporter, known
to be involved in taxane and doxorubicin transport, is
not responsible for the resistant phenotype developed by
ZNF217-overexpressing cells, we aimed to determine
which molecular mechanisms are involved in the
ZNF217-mediated phenotype. A critical determinant in
cellular responses to cytotoxic drugs is the ease with
which tumor cells undergo apoptosis [30]. The two
major apoptotic pathways rely on either signals trans-
duced through death receptors or signals from mito-
chondria. Both pathways are involved in the activation
of a cascade of caspases, and caspase 3 is a major execu-
tioner caspase that cleaves substrates such as PARP,
resulting in caspase-dependent apoptosis [31]. In this
study, we found that ZNF217 attenuates the apoptotic
signals induced by paclitaxel, in association with
decreased caspase 3 activity and PARP cleavage. More
interestingly, ZNF217-mediated protective effects were
associated with alterations in the intrinsic mitochondrial
apoptosis pathway, as demonstrated by the deregulation
of the balance between pro- and anti-apoptotic mem-
bers of the Bcl-2 family. Indeed, in both ZNF217-1 and
ZNF217-2 cells, high constitutive expression levels of
the anti-apoptotic proteins Bcl-2 and Bcl-xL and low
constitutive expression levels of the pro-apoptotic pro-
teins Bad, Bax and Bak were detected. Since ectopic
overexpression of Bcl-2 or Bcl-xL is necessary to confer
resistance to paclitaxel-induced apoptosis [32] and ecto-
pic overexpression of Bad or Bax have been shown to
enhance paclitaxel-induced apoptosis [33], our data
strongly suggest that acquisition of aberrant expression
of several members of the Bcl-2 family may be part of
the mechanisms developed by ZNF217-1 and ZNF217-2
cells to counteract paclitaxel-induced apoptotic signals.
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ZNF217 functions [14], but the ZNF217-driven survival
phenotype observed in this study is p53-independent,
given that MDA-MB-231 cells possess a non functional
mutated p53.
Aurora-A, a serine/threonine kinase located at the
centrosome, is overexpressed in 10-60% of breast can-
cers [29], functions as a pro-survival protein that pro-
motes tumor cell proliferation, counteracts apoptosis
and induces drug resistance in tumor cells [29,34].
Indeed, Aurora-A overexpression has been associated in
cancer cells with spindle checkpoint dysfunction,
increased resistance to paclitaxel and docetaxel [28,29],
increased expression of Bcl-2 [34] or of Bcl-xL [35].
C o n v e r s e l y ,A u r o r ak i n a s ei nhibitors synergize with
paclitaxel to induce apoptosis in ovarian cancer cells
[36]. In this study, we show for the first time that
ZNF217 modulates Aurora-A expression, probably at a
post-transcriptional level. Post-transcriptional mechan-
isms such as phosphorylation-dephosphorylation events
[37] or ubiquitin-dependent proteolysis [38,39] have
been shown to regulate the protein levels of Aurora-A
and to play an important role in the functions of this
protein [40-42]. Thus ZNF217 may modulate Aurora-A
protein turn-over (synthesis or degradation) by still
unknown mechanisms. We also newly demonstrated
that treatment with a potent Aurora-A kinase inhibitor
is able to reverse paclitaxel resistance in ZNF217-over-
expressing breast cancer cells. Altogether, these data
strongly suggest that the oncogenic Aurora-A kinase
could represent a key actor of ZNF217-mediated effects.
Finally, as observed for most of kinase inhibitors, the
Aurora kinase inhibitor III is also able to target (but at
higher concentrations) the activities of other kinases
(Lck, Bmx, IGF-1R and Syk). Thus, one cannot exclude
that these kinases could also be involved in ZNF217-
mediating effects.
Since the AURKA gene is located, like the ZNF217
gene, at 20q13, a region frequently amplified in human
cancers, our finding is of particular interest for several
reasons. Our data suggest that two known oncogenes,
ZNF217 and Aurora-A, may cooperate in breast neo-
plastic progression and chemoresistance, thus revealing
a possible mechanism by which ZNF217 exerts its onco-
genic and protective effects. The positive control of
ZNF217 on Aurora-A could induce a self-reinforcing
amplification of the effect of high levels of ZNF217
expression and/or of increased ZNF217 copy number.
As 20q13 amplified breast tumors can either display
ZNF217 amplification only or both ZNF217 and
AURKA amplifications [5], oneo ft h em e c h a n i s m so f
breast neoplastic progression could involve the coopera-
tion between the two proteins, either through genomic
co-amplification or through ZNF217-mediated regula-
tion of Aurora-A protein expression.
Conclusions
This study demonstrates that ZNF217 counteracts
apoptotic signals other than those induced by DNA
damage stimuli [14], and that the protective effects of
ZNF217 are associated with constitutive alterations in
the balance of Bcl-2 proteins and with constitutive
aberrant overexpression of Aurora-A. Given that
ZNF217 amplifications have been detected in 8-29% of
breast cancers [1] and that high ZNF217 expression
levels are not necessarily correlated to increased
ZNF217 gene copy numbers in breast cancer cells
[4,5,10], increased protein expression of ZNF217 could
represent a new mechanism by which breast cancer
cells without ZNF217 gene amplification become resis-
tant to paclitaxel. Most importantly, our data suggest
that clinical strategies counteracting ZNF217-mediated
effects, either by targeting ZNF217 directly and/or by
targeting its possible key-mediators like Aurora-A,




MCF7 and MDA-MB-231 breast cancer cells were pur-
chased from ATCC and grown according to recommen-
dations in DMEM medium supplemented with 10% fetal
bovine serum (Invitrogen, Cergy Pontoise, Paris). The
identity of MDA-MB-231 cells was confirmed by geno-
mic DNA sequencing (KRAS and TP53 genes) and that
of MCF7 cells by their estrogen receptor and progester-
one receptor status.
MDA-MB-231-ZNF217 stable transfectants
The full-length ZNF217 cDNA was obtained by adding
the missing cDNA sequence, corresponding to the last 6
C-terminal amino acids of the ZNF217 protein, to the
pEGFP-N1-ZNF217 plasmid provided by C. Collins,
then subcloned into the pcDNA6/V5-His plasmid (Invi-
trogen) (pcDNA6/V5-His-ZNF217). MDA-MB-231
breast cancer cells were stably transfected with
pcDNA6/V5-His or pcDNA6/V5-His-ZNF217 plasmids,
then selected in the presence of 20 μg/ml blasticidin
(Invitrogen).
Real-time quantitative PCR (RTQ-PCR)
Total RNA from cell culture was prepared using the
RNeasy Mini Kit (Qiagen, Hilden, Germany). One
microgram of total RNA was reversed-transcribed, and
RTQ-PCR measurements were performed as described
previously [43].
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Western-blot analysis was performed as previously
described [43]. For each sample, total proteins were
quantified using a Bradford protein assay and 50 μgo f
total protein were separated on SDS/PAGE gels before
transferring to a PVDF membrane (Sigma-Aldrich, St
Quentin Fallavier, France). ZNF217 antibody was
obtained from C. Collins [14], Cyclin D1, PARP, Bax
and Aurora-A antibodies were from Cell Signaling
(Beverly, MA, USA), Cyclin E2 and Bcl-xL antibodies
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA), Bcl-2 antibody from Neomarker (Fremont, CA,
USA), Bad antibody from BD Biosciences (Franklin
Lakes, NJ, USA), Bak and Cyclin E1 antibodies from
Calbiochem (San Diego, CA, USA) and Cyclin A2 and
a-tubulin antibodies from Sigma Chemical Co. (St.
Louis, MO, USA). All western-blots presented are from
one experiment representative of at least two indepen-
dent experiments and cell lysates, and at least three wes-
tern-blots. Signals were quantified by pixel densitometry
using the VisionWorksLS Analysis Software.
Gene silencing
Stealth™ siRNAs (siRNA-A and siRNA-B) targeting
ZNF217 and scrambled control RNA (scrambled) were
obtained from Invitrogen. Five nanomoles of ZNF217-
siRNAs or scrambled were transfected into cell lines
with lipofectamine RNAimax (Invitrogen).
Cell proliferation analysis
Cells (4 000 cells per well) were plated onto a 96-well
plate. Proliferating cells were analyzed using a Cell Pro-
liferation ELISA 5-bromodeoxyuridine (BrdU) Kit
(Roche, Meylan, France) as previously described [44].
Tumor growth assay
A total of 2×10
6 MDA-MB-231/pcDNA6 or ZNF217-1
cells were suspended in PBS/matrigel v/v (BD Bios-
ciences) and injected into the mammary fat pad of 4-
week-old female Swiss nude (nu/nu) mice (Charles
River, L’arbresle, France) (control xenografts n = 6 and
ZNF217 xenografts n = 7). Tumors were measured with
calipers every 3-4 days. All animal studies were per-
formed in accordance with the European Union guide-
lines and use committee of Centre Léon Bérard.
Cytotoxicity assay
Cells (8 000 cells per well) were plated onto a 96-well
plate, treated for 4 days with 10
-12 to 10
-6 M of pacli-
taxel (Paxene®, Ivax, Miami, USA). Cell viability was
then assessed with the CellTiter 96 AQueous One Solu-
tion Cell Proliferation assay (Promega, Madison, WI,
USA). Cytotoxic experiments were also conducted as
described above in the presence of Aurora kinase
inhibitor III, a potent inhibitor of Aurora-A (Merck,
Nottingham, UK), alone or combined with 2.5 nM
paclitaxel.
Flow cytometry analysis of ABCB1 protein expression
levels
ABCB1 protein levels were quantified by flow cytometry in
ABCB1-positive control K562-R7, MDA-MB-231/
pcDNA6, ZNF217-1 and ZNF217-2 cells using the
ABCB1-C219 (phycoerythrin PE)-conjugated antibody
(Santa Cruz) according to the manufacturer’si n s t r u c t i o n s .
Efflux assay
At the end of uptake phase (30 min, 37°C), daunorubi-
cin (17 μM DNR, DaunoXome®, San Dimas, CA, USA)
was removed and cells were re-incubated for 1 h in
DNR-free medium in the presence or absence of 4 μg/
ml cyclosporin A (CSA). After trypsination, DNR fluor-
escence was monitored with a FACscan flow cytometer
(Becton Dickinson, Mountain View, CA, USA) as pre-
viously described [23].
Detection of apoptosis by annexin-V staining
The cells were grown for 3 days and treated or not with
10 nM or 100 nM of paclitaxel. Apoptotic cells were
detected using the Annexin-V-FLUOS Staining Kit
(Roche). FITC fluorescence was then analyzed in 2×10
4
cells by a FACscan flow cytometer. The percentage of
apoptotic cells was determined by analysis with cell-
Quest
(tm) software (Becton Dickinson).
Caspase 3 activity assay
Briefly, cells were treated or not with 100 nM of pacli-
taxel for 10 h. Caspase 3 activity was determined using
the Caspase-3/CPP32 fluorometric assay kit (Clinis-
ciences, Montrouge, France).
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